Günter Niegisch1, Alessandro Nini1,2, René Michalski1,3, Alina Henn1,4, David Mally1, Peter Albers1, Robert Rabenalt1. 1. Department of Urology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany. 2. Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. 3. Department of Urology, Ev. Krankenhaus Oberhausen, Oberhausen, Germany. 4. Genetikum, Stuttgart, Germany.
Abstract
BACKGROUND: Data on oncological follow-up after robotic-assisted radical cystectomy (RARC) have been reported only scarcely and individual studies have reported an increase in early recurrences and atypical recurrences. PATIENTS AND METHODS: Clinical data of 89 patients with RARC were compared to 59 patients with open radical cystectomy (ORC) at a single institution. Two-year cancer-specific (2y-CSS) and 2-year overall survival (2y-OS) related to histopathological tumor stage of RARC patients calculated by Kaplan-Meier method were compared to ORC patients using log-rank test. Early clinical recurrence rate (eCR, progression ≤6 months post-cystectomy) and metastatic pattern of both groups were compared by chi-square test. RESULTS: Median follow-up 32 months (RARC) and 47.5 months (ORC), both groups were balanced in baseline characteristics. For RARC pts, -2y-OS and CSS-free survival rates were 80 and 90%, for ORC pts 65 and 71% (all p > 0.05). Margin status was not significantly different. eCR was observed in 10 out of 89 (11%) RARC pts and in 7 out of 59 (12%) ORC pts (p = 0.9). No difference in atypical metastases was seen between groups. CONCLUSION: Two-year oncological outcomes of RARC patients are comparable to ORC patients without differences regarding ePR or metastatic pattern.
BACKGROUND: Data on oncological follow-up after robotic-assisted radical cystectomy (RARC) have been reported only scarcely and individual studies have reported an increase in early recurrences and atypical recurrences. PATIENTS AND METHODS: Clinical data of 89 patients with RARC were compared to 59 patients with open radical cystectomy (ORC) at a single institution. Two-year cancer-specific (2y-CSS) and 2-year overall survival (2y-OS) related to histopathological tumor stage of RARC patients calculated by Kaplan-Meier method were compared to ORC patients using log-rank test. Early clinical recurrence rate (eCR, progression ≤6 months post-cystectomy) and metastatic pattern of both groups were compared by chi-square test. RESULTS: Median follow-up 32 months (RARC) and 47.5 months (ORC), both groups were balanced in baseline characteristics. For RARC pts, -2y-OS and CSS-free survival rates were 80 and 90%, for ORC pts 65 and 71% (all p > 0.05). Margin status was not significantly different. eCR was observed in 10 out of 89 (11%) RARC pts and in 7 out of 59 (12%) ORC pts (p = 0.9). No difference in atypical metastases was seen between groups. CONCLUSION: Two-year oncological outcomes of RARC patients are comparable to ORC patients without differences regarding ePR or metastatic pattern.
Authors: Angelo Porreca; Katie Palmer; Walter Artibani; Alessandro Antonelli; Lorenzo Bianchi; Eugenio Brunocilla; Aldo Massimo Bocciardi; Maurizio Brausi; Gian Maria Busetto; Marco Carini; Giuseppe Carrieri; Antonio Celia; Luca Cindolo; Giovanni Cochetti; Renzo Colombo; Ettore De Berardinis; Ottavio De Cobelli; Fabrizio Di Maida; Amelio Ercolino; Franco Gaboardi; Antonio Galfano; Andrea Gallina; Michele Gallucci; Carlo Introini; Ettore Mearini; Andrea Minervini; Francesco Montorsi; Gennaro Musi; Giovannalberto Pini; Riccardo Schiavina; Silvia Secco; Sergio Serni; Claudio Simeone; Giovanni Tasso; Daniele D'Agostino Journal: BMC Cancer Date: 2021-01-11 Impact factor: 4.430